Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: S01ED51

Ganfort(bimatoprost;timolol)

Glaucoma, Open-Angle;Ocular Hypertension

Marketing Authorisation Holder: AbbVie Deutschland GmbH & Co. KG

EMA Authorisation: 19/05/2006

INN: bimatoprost;timolol

Indication

Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Ganfort — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.